# Merkel cell carcinoma: Clinicopathological analysis of three patients and literature review

**Authors:** Ting Xu, Xue Meng, Shuai Luo, Yao Li, Jinjing Wang

PMC · DOI: 10.1515/biol-2025-1168 · Open Life Sciences · 2025-11-07

## TL;DR

This paper analyzes three cases of Merkel cell carcinoma, a rare and aggressive skin cancer, focusing on their clinical features, pathology, and treatment outcomes.

## Contribution

The study provides a detailed clinicopathological and immunophenotypic analysis of three MCC cases, highlighting diagnostic and treatment insights.

## Key findings

- MCC tumors showed similar morphology with intradermal masses, necrosis, and lymphocyte infiltration.
- Immunophenotyping revealed CK(+), CD56(+), Syn(+), and EMA(+) markers with high Ki-67 proliferation indices.
- Two patients were CgA negative, and one showed CK20 positivity, indicating variability in immunophenotype.

## Abstract

To investigate the clinicopathological features of three patients with Merkel cell carcinoma (MCC). The clinicopathological features, immunophenotypes, diagnosis and differential diagnosis, treatment, and prognosis of the three patients with MCC were analyzed retrospectively. Among the three patients, two were male and one was female. The age range of the patients was 55–79 years, while their mean age was 66.6 years. The maximum and mean tumor diameters were 1.8–2.5 cm and 2.1 cm, respectively. The tumors were located in surface areas such as the face and forearm. The tumor masses were mostly round, with a gray, solid appearance and qualitative sections. Microscopic examination revealed that the MCCs of the three patients had roughly the same morphology. Light microscopy indicated that the MCCs appeared as an intradermal mass with a narrow “Grenz band” separated from the epidermis, often accompanied by necrosis (apoptotic bodies) and patchy lymphocyte infiltration. Histological assessment of the MCCs showed monomorphic cell hyperplasia with cables, trabeculae, or sheet formation, hyperchromatic nuclei, vacuoles, cytoplasm with a “salt and pepper” appearance, and nuclear division. Immunophenotyping found tumor cells that were CK (+), CD56 (+), Syn (+), EMA (+), β-catenin (membrane +), LCA (−), CD99 (−), S100 (−), HMB-45 (−), SOX-10 (−), TTF-1 (−), CDX-2 (−), and CD34 (−), along with a Ki-67 proliferation index of 60–70%. Of the three patients with MCC, two were immunophenotypic CgA negative and one was positive. Additionally, two immunophenotypes exhibited CK20 negativity, and one showed paranuclear punctate positivity for CK20. MCC is a highly malignant cutaneous neuroendocrine carcinoma, requiring the combination of pathological morphology examination and immunophenotyping to confirm the diagnosis. Moreover, the primary MCC treatment of surgical treatment should be supplemented with chemotherapy and/or local radiotherapy to alleviate its poor prognosis, easy recurrence or metastasis, and high mortality.

## Linked entities

- **Proteins:** CHKA (choline kinase alpha), NCAM1 (neural cell adhesion molecule 1), FYN (FYN proto-oncogene, Src family tyrosine kinase), ETFA (electron transfer flavoprotein subunit alpha), ctnnb1.S (catenin beta 1 S homeolog), CLTA (clathrin light chain A), CD99 (CD99 molecule (Xg blood group)), S100A1 (S100 calcium binding protein A1), PMEL (premelanosome protein), SOX10 (SRY-box transcription factor 10), TTF1 (transcription termination factor 1), CDX2 (caudal type homeobox 2), CD34 (CD34 molecule), CGA (glycoprotein hormones, alpha polypeptide), KRT20 (keratin 20)
- **Diseases:** Merkel cell carcinoma (MONDO:0019210), MCC (MONDO:0019210)

## Full-text entities

- **Genes:** NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CD99 (CD99 molecule (Xg blood group)) [NCBI Gene 4267] {aka HBA71, MIC2, MIC2X, MIC2Y, MSK5X}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, CHGA (chromogranin A) [NCBI Gene 1113] {aka CGA, PHE5, PHES}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, CLTA (clathrin light chain A) [NCBI Gene 1211] {aka LCA}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, SYNM (synemin) [NCBI Gene 23336] {aka DMN, SYN}, CD34 (CD34 molecule) [NCBI Gene 947], CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, SOX10 (SRY-box transcription factor 10) [NCBI Gene 6663] {aka DOM, PCWH, SOX-10, WS2E, WS4, WS4C}
- **Diseases:** hyperplasia (MESH:D006965), cutaneous neuroendocrine carcinoma (MESH:D018278), MCC (MESH:D015266), metastasis (MESH:D009362), tumor (MESH:D009369), necrosis (MESH:D009336)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12619635/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12619635/full.md

---
Source: https://tomesphere.com/paper/PMC12619635